Rigosertib Reverses Hypertrophic Cardiomyopathy in Noonan Syndrome
It is suggested rigosertib normalizes and reverses RASopathy-associated HCM and other NS-associated syndromic features, supporting its development as a promising treatment for RAF1-associated HCM and, potentially, other RASopathy-dependent pathologies.